Skip to content

KLRS KLRS Restricted Cash

Restricted Cash at other companies

Merck & Co. logo
Merck & Co.MRK
$71M-31.1%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$150K0.0%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.61M0.0%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$6.18M0.0%
Regenxbio logo
RegenxbioRGNX
$2.03M0.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's restricted cash?
KLRS (KLRS) reported restricted cash of $500K in Q1 2026.
How has KLRS's restricted cash changed year-over-year?
KLRS's restricted cash decreased by 0.0% year-over-year, from $500K to $500K.
What is the long-term trend for KLRS's restricted cash?
Over 4 years (2021 to 2025), KLRS's restricted cash has grown at a -12.5% compound annual growth rate (CAGR), from $852K to $499K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.